BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//Pharma Journalist - ECPv6.16.2//NONSGML v1.0//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-ORIGINAL-URL:https://www.pharmajournalist.com
X-WR-CALDESC:Events for Pharma Journalist
REFRESH-INTERVAL;VALUE=DURATION:PT1H
X-Robots-Tag:noindex
X-PUBLISHED-TTL:PT1H
BEGIN:VTIMEZONE
TZID:Asia/Kolkata
BEGIN:STANDARD
TZOFFSETFROM:+0530
TZOFFSETTO:+0530
TZNAME:IST
DTSTART:20220101T000000
END:STANDARD
END:VTIMEZONE
BEGIN:VEVENT
DTSTART;VALUE=DATE:20230221
DTEND;VALUE=DATE:20230224
DTSTAMP:20260516T051016
CREATED:20221027T104330Z
LAST-MODIFIED:20221027T104330Z
UID:35633-1676937600-1677196799@www.pharmajournalist.com
SUMMARY:Retinal Vascular Disease Drug Development Summit
DESCRIPTION:Retinal Vascular Disease Drug Development Summit is an event dedicated to creating a community space dedicated to overcoming the current challenges in drug development for retinal vascular diseases. \nThe management of these diseases has made remarkable advancements in previous years\, but the burden on patients remains high\, posing a need to develop novel therapeutics and delivery mechanisms that improve the efficacy and durability of anti-VEGF drugs and beyond. \nProviding you with an in-depth coverage of technical insights of anti-VEGF\, innovative non-VEGF targeting therapeutics for wet-AMD\, DME\, DR and RVO\, the Retinal Vascular Disease Drug Development Summit will address the specific challenges in utilizing preclinical models for retinal vascular disease\, understand key regulatory requirements\, and learn how to run effective clinical trials that utilize appropriate endpoints. \nJoin your colleagues from across R&D\, preclinical\, translational and clinical teams across the biopharmaceutical industry to streamline your drug development and address the significant and increasing unmet medical need. \nTo know more visit: https://ter.li/7xp7xc
URL:https://www.pharmajournalist.com/event/retinal-vascular-disease-drug-development-summit/
LOCATION:Hilton Boston Logan Airport\, One Hotel Dr\, Boston\, MA\, 02128\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20230221
DTEND;VALUE=DATE:20230223
DTSTAMP:20260516T051016
CREATED:20221102T085213Z
LAST-MODIFIED:20221102T085213Z
UID:35698-1676937600-1677110399@www.pharmajournalist.com
SUMMARY:6th CAR-TCR Summit Europe
DESCRIPTION: Join us in London this February to connect with those trailblazing the next wave of CAR and TCR based approaches from pre-clinical development with in vivo engineering and regulatory fast-track strategies to streamlined analytics and automation to make CAR and TCR therapies better\, and faster. \n \nTake advantage of cutting-edge innovation from global biopharma leaders in cell armouring\, combination approaches and multiplexing gene engineering to improve cell durability and trafficking across allogeneic and solid tumour indications\, and leave understanding the technical strategies to build automated\, closed-system manufacturing processes to ensure vein to vein time is less than a week. \nPromising data-driven case studies outlining next generation product design\, clinical trial set-up and manufacturing processes\, this meeting is your go-to to comprehensively assess the emerging improvements of CAR and TCR based therapies.  \nSee the full agenda here: https://ter.li/ulbn8o
URL:https://www.pharmajournalist.com/event/6th-car-tcr-summit-europe/
LOCATION:ExCeL London\, Royal Victoria Dock\, 1 Western Gateway\, London\, E16 1XL\, United Kingdom
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20230221
DTEND;VALUE=DATE:20230224
DTSTAMP:20260516T051016
CREATED:20221124T112536Z
LAST-MODIFIED:20221124T113110Z
UID:35914-1676937600-1677196799@www.pharmajournalist.com
SUMMARY:3rd Annual Gene Therapy for Muscular Disorders Summit
DESCRIPTION:The past twelve months have seen an unprecedented level of excitement\, investment\, and progression within the gene therapy for muscular disorders field. As the industry endeavours to move gene therapy treatment through the preclinical and clinical pipeline\, in context of reducing toxicity and increasing efficacy\, attending the 3rd Annual Gene Therapy for Muscular Disorders Summit has never been so crucial. \nThis year’s summit will return to Boston to reunite 100+ leading experts in biotech\, pharma and academia to continue to develop strategies to deliver safer and more effective gene therapies to muscle cells. \nThis summit will encompass all aspects of preclinical development and highlight the obstacles in clinical trials\, enabling you to address and overcome these challenges. \nTo know more visit: https://ter.li/wi2a51
URL:https://www.pharmajournalist.com/event/3rd-annual-gene-therapy-for-muscular-disorders-summit/
LOCATION:Hilton Boston Back Bay\, 40 Dalton St\, Boston\, MA\, 02115\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20230221
DTEND;VALUE=DATE:20230224
DTSTAMP:20260516T051016
CREATED:20230202T105848Z
LAST-MODIFIED:20230202T105848Z
UID:36454-1676937600-1677196799@www.pharmajournalist.com
SUMMARY:11th Alzheimer’s & Parkinson’s DD Summit
DESCRIPTION:Welcome to the 11th Alzheimer’s & Parkinson’s Drug Development Summit \n \nWith a surge in preclinical investment\, fresh news of clinical pipeline progressions\, and a new era of therapies pending FDA approvals from Biogen\, Eisai\, and Denali Therapeutics\, 2022 has put neurodegenerative drug development back on the map. \nBuilding on the field’s momentum\, we are delighted to bring back the 11th Alzheimer’s & Parkinson’s Drug Development Summit\, dedicated to overcoming the translational challenges of targeting neurodegenerative mechanisms. This summit will unite neurodegenerative biopharma experts from discovery\, preclinical\, translational\, and clinical backgrounds to showcase the latest breakthroughs in Alzheimer’s\, Parkinson’s\, and related neurological disorders in 2022 and 2023 \nTo know more visit: https://ter.li/x0w74p
URL:https://www.pharmajournalist.com/event/11th-alzheimers-parkinsons-dd-summit/
LOCATION:Hyatt Centric Fisherman’s Wharf\, San Francisco\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:Info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20230222
DTEND;VALUE=DATE:20230224
DTSTAMP:20260516T051016
CREATED:20221205T103427Z
LAST-MODIFIED:20221205T103427Z
UID:35996-1677024000-1677196799@www.pharmajournalist.com
SUMMARY:2nd Next Generation Kinase Inhibitors Summit
DESCRIPTION:Since Kinase inhibitors have proven to be efficacious and approvable targets\, fuelling recent investment into this exciting space as their therapeutic targeting is explored beyond oncology. However\, increasing resistance to existing programs and safety bottlenecks threaten further progress. The next wave of kinase targets depends on innovation. \nJoin the 2nd Next Generation Kinase Inhibitors Summit to connect with experts across discovery\, R&D\, and clinical medicine to discuss how to accelerate the next generation of kinase inhibitor drugs to market\, which displays maximal therapeutic efficacy and durable clinical responses. \nKey Topics: \n\nAssay Development\, Kinome Exploration & and Kinase-Focussed Drug Discovery Principles\nOvercoming Tumor Resistance\, Managing the Tumor Microenvironment\, and Improving Durability\nExploiting the RAS/MAPK Signalling Pathway\nMultikinase and Combination Therapies to Overcoming Resistance\nTargeting Established Pharmacological Mechanisms in Alternative Indications Beyond Oncology to Meet Unmet Needs\n\nDon’t miss this opportunity to join & network with 100+ Kinase Biology Experts under one roof\, hear from 18+ expert speakers from the space and showcase your work at the Scientific Poster Session. \nThis meeting is FREE for drug developers and researchers! \nTo know more visit: https://ter.li/sreltb
URL:https://www.pharmajournalist.com/event/2nd-next-generation-kinase-inhibitors-summit/
LOCATION:Boston Park Plaza\, 50 Park Plaza\, Boston\, MA\, 02116\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
END:VCALENDAR